Lion Point Capital’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Lion Point Capital’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-500,000	Closed	-$2.29M	–	51
2021 Q3	$2.29M	Hold	500,000	–	–	0.61%	30
2021 Q2	$2.22M	Hold	500,000	–	–	0.53%	27
2021 Q1	$3.64M	Hold	500,000	–	–	0.89%	22
2020 Q4	$3.81M	Hold	500,000	–	–	0.79%	18
2020 Q3	$4.54M	Hold	500,000	–	–	1.02%	17
2020 Q2	$4.23M	Hold	500,000	–	–	1.06%	19
2020 Q1	$2.47M	Hold	500,000	–	–	0.86%	21
2019 Q4	$3.6M	Hold	500,000	–	–	0.55%	22
2019 Q3	$5.41M	Hold	500,000	–	–	0.89%	20
2019 Q2	$6.5M	Hold	500,000	–	–	1.04%	22
2019 Q1	$4.94M	Hold	500,000	–	–	0.84%	19
2018 Q4	$5.2M	Buy	+500,000	New	+$6.04M	1.13%	25

Other funds holding LOGC

OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return

Franklin Resources

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Samlyn Capital New York $5.82B AUM 36.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Eversept Partners New York $1.52B AUM 121.13% 1-Year Est. Return

Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return